PMLiVE1h
Navigating market access: Launch strategies and health economic modelling for medical devices – a live panel discussion
Discover how health economics can support successful Medical Device launch, proposition development, and market access. Join ...
PMLiVE23h
Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy
Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year ...
PMLiVE23h
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
PMLiVE23h
Key clinical trial trends – EU vs US perspectives
Real-time payments: US respondents place slightly higher importance on speed of payment to participants (87% US sites and 81% ...